VCEL Q2 2023 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena

VCELVericel Corporation

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M+24.0% YoY

Gross Profit

$30M65.2% margin

Operating Income

-$6M-13.0% margin

Net Income

-$5M-10.9% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+12.0%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$6M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$311M

Total Liabilities

$112M

Stockholders' Equity

$199M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$37M	+24.0%
Gross Profit	$30M	$23M	+31.0%
Operating Income	-$6M	-$9M	+34.4%
Net Income	-$5M	-$9M	+44.0%

Revenue Segments

MACI Implants And Kits

$36M100%